Bernstein downgraded Vertex Pharmaceuticals to Market Perform from Outperform. With the Phase 3 acute pain data now behind investors, the company’s “thinning catalyst calendar” and current valuation that does not leave significant upside warrants a downgrade, the analyst tells investors in a research note. Vertex reports next Monday, and Bernstein also sees some risk that expense guidance disappoints like last year.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VRTX:
- QQQ ETF Update, 2/1/2024
- UPS downgraded, Stryker upgraded: Wall Street’s top analyst calls
- Vertex Pharmaceuticals price target lowered to $378 from $379 at Canaccord
- Vertex cut to Hold at Maxim on less confidence in VX-548 being blockbuster
- Vertex Pharmaceuticals price target raised to $500 from $450 at Oppenheimer
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue